pharma · NASH With Fibrosis · NASH - Nonalcoholic Steatohepatitis · HEPA
Hepion Pharmaceuticals
Hepion Pharmaceuticals clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Morristown, USA
- Employees
- 4
- Programs
- 5
- Drugs
- 2
- Patents
- 1
Hepion Pharmaceuticals projects
5 ClinicalTrials.gov programs sponsored by Hepion Pharmaceuticals.
Hepion Pharmaceuticals has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CRV431 75mg
Hepion Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis
1 trial -
Rencofilstat
Hepion Pharmaceuticals
Nonalcoholic Steatohepatitis (NASH)
1 trial -
rencofilstat, 75 mg
Hepion Pharmaceuticals
NASH With Fibrosis
1 trial -
CRV431
Hepion Pharmaceuticals
Hepatitis B
1 trial -
[14C]-rencofilstat 225mg
Hepion Pharmaceuticals
NASH With Fibrosis
1 trial
Frequently asked questions
How many clinical projects does Hepion Pharmaceuticals have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.